AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01621477
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
Trial: NCT02851745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00217737
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00217737
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01948531
Drug: Gynomunal® gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
Trial: NCT02669862
Drug: A-101 Solution 40
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02669862
Drug: A-101 Solution 45
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02669862
Drug: Vehicle Solution
RxNorm normalized name: compounding vehicle solution sugar free no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02397694
Drug: BIC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT02397694
Drug: DTG Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT02397694
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg FDC tablet administered orally once daily
Trial: NCT01694420
Drug: (FDC) ELV/COBI/FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment
Trial: NCT01566643
Drug: RA5-RACM7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Trial: NCT02226601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days perioperative Placebot once a day
Trial: NCT03483363
Drug: topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)
RxNorm normalized name: gentamicin Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractures will be irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.
Trial: NCT00394563
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01952314
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
Trial: NCT03283384
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).
Trial: NCT01566643
Drug: RA3-RACM7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Trial: NCT01566643
Drug: RA7-RACM7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Trial: NCT04669041
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT04669041
Drug: SPC ezetimibe/rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT04669041
Drug: Rosuvastatin active capsule
RxNorm normalized name: rosuvastatin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Capsule Route of administration: Oral
Trial: NCT04669041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Trial: NCT04669041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Capsule Route of administration: Oral
Trial: NCT04446923
Drug: Hand antisepsis by scrub
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical Hand scrubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
Trial: NCT00758966
Drug: Fluoxetine 60 mg
RxNorm normalized name: fluoxetine 60 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
Trial: NCT00758966
Drug: Naltrexone 32 mg and fluoxetine 60 mg
RxNorm normalized name: fluoxetine hydrochloride 32 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
Trial: NCT00736437
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment applied 6 times daily over the UVR exposed area
Trial: NCT03656588
Drug: a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
Trial: NCT00015873
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00015873
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00015873
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03449446
Drug: FIR
RxNorm normalized name: Firox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tablet administered orally once daily without regard to food
Trial: NCT03449446
Drug: Placebo to match FIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily without regard to food
Trial: NCT03449446
Drug: Placebo to match CILO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily without regard to food
Trial: NCT03449446
Drug: Placebo to match SEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily without regard to food
Trial: NCT03883802
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months treatment regimen
Trial: NCT01206010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
Trial: NCT00289120
Drug: Cola beverage
RxNorm normalized name: cola extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
Trial: NCT00286026
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
Trial: NCT00553735
Drug: Arificial Tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial Tear - three times a day for 18 months.
Trial: NCT00451646
Drug: SMOF lipid and Intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 g, 5-7 days, 28 days
Trial: NCT03765788
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)
Trial: NCT03765788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
Trial: NCT01057069
Drug: Doxorubicin, cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
Trial: NCT01057069
Drug: Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
Trial: NCT00651404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
Trial: NCT02648958
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group received the normal saline infusion
Trial: NCT03009201
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01151046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
Trial: NCT00610610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same shape Placebo
Trial: NCT01940991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, Dose B; dose applied to the lateral canthal lines
Trial: NCT01917916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous (s.c.) injection.
Trial: NCT00216138
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m2 po bid, days 1-14
Trial: NCT04007198
Drug: EQ001 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EQ001 Placebo
Trial: NCT02147964
Drug: Testosterone 1% Gel
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone 1% gel 5g daily for 4 months \[all subjects\]
Trial: NCT01863407
Drug: DAM
RxNorm normalized name: dAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: composed of dexamethasone, allantoin and metronidazole
Trial: NCT01863407
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline 250ml
Trial: NCT02500043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
Trial: NCT01371747
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
Trial: NCT00411411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01415102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled
Trial: NCT03395457
Drug: Care as usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of usual pharmacological care for chronic migraine
Trial: NCT04348695
Drug: Ruxolitinib plus simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days
Trial: NCT00002780
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00948662
Drug: Placebo of SAM-760
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAM-760 matching placebo capsule, single dose, 1 day,
Trial: NCT03428412
Drug: TCM placebo and conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.
Trial: NCT00319228
Drug: Plasma-derived AT-III concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan.
Trial: NCT00696787
Drug: Lyrica® (Pregabalin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00696787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01261923
Drug: Alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
Trial: NCT01146756
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
Trial: NCT00005050
Drug: ethynyluracil
RxNorm normalized name: 5-Ethynyluracil
DrugBank: Eniluracil (DB03516)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005050
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00702156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
Trial: NCT00039442
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT01911845
Drug: ABT-450/r/ABT-267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Trial: NCT01911845
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00131495
Drug: Testosterone (transdermal patches)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone patch (300mcg/day, changed twice a week for one year
Trial: NCT02765763
Drug: 24/7 Barrier Repair Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02765763
Drug: 8-in-1 BioSerum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02765763
Drug: Null Formula 24/7 Barrier Repair Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02765763
Drug: Null Formula 8-in-1 BioSerum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03059797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
Trial: NCT02213653
Drug: ARM B: IV iron + epoietin zeta sequence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~* carboxymaltose ferric (Ferinject ®) at week 1~  * Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~ * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1.
Trial: NCT02213653
Drug: ARM C : single epoietin zeta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
Trial: NCT01611857
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.
Trial: NCT00582010
Drug: inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled 80ppm for duration of surgery.
Trial: NCT03201445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match filgotinib tablet administered orally once daily
Trial: NCT03201445
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
Trial: NCT02934191
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
Trial: NCT02934191
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
Trial: NCT04166565
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
Trial: NCT02806115
Drug: Acetic Acid
RxNorm normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The concentration of acetic acid used in this study is 1.5%.
Trial: NCT01931878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
Trial: NCT00237393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
Trial: NCT00841828
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00789035
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01425658
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .